Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting

GERMANTOWN, Md., Nov. 16, 2017 (GLOBE NEWSWIRE) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that data from the Company’s Phase 2 study of NSI-189 in patients with major depressive disorder will …

US, EU Talk Tough on Cambodia

Preferential access to Cambodia’s biggest export market could be removed and senior government officials banned from doing business with U.S. companies in response to a court ordered dissolution of the country’s opposition, statements released Friday suggest.

Cambodia’s Supreme Court ruled …